1. Scrip

PTC soars on CHMP nod for Translarna

 
• By Alexandra Shimmings

Shares in PTC Therapeutics shot up by as much as 117% to $33.18 on news that its novel treatment for Duchenne muscular dystrophy Translarna (ataluren) has finally received the go-ahead for approval from the EU's CHMP.

Shares in PTC Therapeutics shot up by as much as 117% to $33.18 on news that its novel treatment for Duchenne muscular dystrophy Translarna (ataluren) has finally received the go-ahead for approval from the EU's CHMP.

Reversing an earlier decision, the committee says a conditional approval of the drug is warranted in nonsense mutation DMD patients aged five years and older who are able to walk,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Musculoskeletal

More from Therapy Areas

ASCO: J&J Banks On T-Cell Engager’s Safety In Prostate Cancer

 
• By Andrew McConaghie

The company highlighted the KLK2-targeting agent’s safety at ASCO but it may have to rely on combinations to make pasritamig competitive.

ASCO: Regeneron Looks To Become Bigger Immuno-Oncology Player

 
• By Alaric DeArment

The drugmaker presented oral abstracts at the meeting for Libtayo in adjuvant cutaneous squamous-cell carcinoma and linvoseltamab in multiple myeloma.

ASCO: Lupin Presents Early Data On PRMT5 Inhibitor

 
• By Vibha Ravi

ASCO sees the debut of Lupin’s PRMT5 inhibitor candidate LRNP7457, currently in Phase I studies in India. While no drug with this mechanism of action has been approved anywhere so far, several candidates are in clinical trials.